Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Exubera unpopular in Germany

The Institute of Quality and Efficiency in Health Care (IQWiG), the German equivalent of NICE, has completed a Rapid Review of Inhaled Insulin (Exubera)®.

The report aimed to compare inhaled insulin to subcutaneous insulin over several patient-relevant endpoints including HbA1c control, quality of life, treatment satisfaction, hypoglycaemia, adverse drug events and prevention of complications.

The report concluded that:

  • the risks of hypoglycaemia may be higher
  • long term treatment risks are unclear
  • reductions in the number of injections may not improve patient satisfaction or quality of life

IQWiG recommend that additional work needs to be undertaken in these areas to allow a more conclusive evaluation to be completed.

Action: Clinicians involved in treating diabetes may wish to be aware of the latest reviews of inhaled insulin. A Technology Appraisal from NICE is due in October 2006.

Share 'Exubera unpopular in Germany' on Email Share 'Exubera unpopular in Germany' on Delicious Share 'Exubera unpopular in Germany' on Digg Share 'Exubera unpopular in Germany' on Facebook Share 'Exubera unpopular in Germany' on Google+ Share 'Exubera unpopular in Germany' on reddit Share 'Exubera unpopular in Germany' on StumbleUpon Share 'Exubera unpopular in Germany' on Twitter

atomic-wealth

One Comments to “Exubera unpopular in Germany”

  1. Thanks for that Matthew.

    Comment by Anthony — May 23, 2006 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,309 spam comments.

atomic-wealth
fond-illness
summer